{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cui K"],"funding":["National Natural Science Foundation of China (National Science Foundation of China)"],"pagination":["756-770"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12449461"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["133(6)"],"pubmed_abstract":["<h4>Background</h4>Hyperactive ribosome biogenesis is a hallmark of tumours. Current ribosome-related studies are concentrated on cancer cells. Ribosomes can regulate both tumour and non-cancer cells within the tumour microenvironment, yet the immunomodulatory effects of cellular ribosome biogenesis blockade remain inadequately understood.<h4>Methods</h4>We performed ribosome-targeting therapy utilizing CX-5461, an effective and acknowledged selective inhibitor of ribosome biogenesis, in immunocompetent in vivo models and submitted for single-cell RNA sequencing (scRNA-seq). Additional large-scale human scRNA-seq data, in-house clinical samples and assays were used.<h4>Results</h4>Ribosome inhibition elevated lymphoid cell cytotoxic granule secretion and macrophage pro-inflammation reprogr"],"journal":["British journal of cancer"],"pubmed_title":["Targeting ribosomes reprograms the tumour microenvironment and augments cancer immunotherapy."],"pmcid":["PMC12449461"],"funding_grant_id":["82303115","82472671","T2250710184"],"pubmed_authors":["Wan Q","Cui K","Zhu Y","Lu X","Wang C","Li Q","Gong Z","Zhang Q","Tang H","Zhang Y","Liu B","Gong L","Shen R"],"additional_accession":[]},"is_claimable":false,"name":"Targeting ribosomes reprograms the tumour microenvironment and augments cancer immunotherapy.","description":"<h4>Background</h4>Hyperactive ribosome biogenesis is a hallmark of tumours. Current ribosome-related studies are concentrated on cancer cells. Ribosomes can regulate both tumour and non-cancer cells within the tumour microenvironment, yet the immunomodulatory effects of cellular ribosome biogenesis blockade remain inadequately understood.<h4>Methods</h4>We performed ribosome-targeting therapy utilizing CX-5461, an effective and acknowledged selective inhibitor of ribosome biogenesis, in immunocompetent in vivo models and submitted for single-cell RNA sequencing (scRNA-seq). Additional large-scale human scRNA-seq data, in-house clinical samples and assays were used.<h4>Results</h4>Ribosome inhibition elevated lymphoid cell cytotoxic granule secretion and macrophage pro-inflammation reprogr","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-07-15T05:55:38.994Z","creation":"2026-06-30T03:16:26.749Z"},"accession":"S-EPMC12449461","cross_references":{"pubmed":["40646287"],"doi":["10.1038/s41416-025-03109-y"]}}